After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophilic Gastrointestinal Diseases
Allakos Inc (NASDAQ: ALLK) has reported data from the EoDyssey Phase 3 study of lirentelimab in patients with eosinophilic duodenitis (EoD).